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ABSTRACT
Background: Risk for developing metabolic syndrome
(MeS) after delivery is high among women with
gestational diabetes mellitus (GDM), but little is known
about development of MeS among women with risk
factors for GDM during pregnancy. In the present
study, we studied the prevalence of MeS 7 years
postpartum among women with GDM risk factors
during pregnancy, women with early GDM diagnosis
and women without GDM risk factors. We also
analysed the early pregnancy risk factors associated
with MeS.
Methods: A Finnish cluster randomised controlled
GDM prevention trial was conducted in 2007–2009.
The prevalence of MeS according to International
Diabetes Federation criteria was determined in the
follow-up study 7 years after original trial. Eligible
participants (n=289) in 4 study groups (intervention
(n=83) and usual care (n=87) with GDM risk factors;
early GDM (n=51), and healthy control without GDM
risk factors (n=68)) were evaluated for MeS. Binary
logistic regression models were used to analyse risk
factors associated with MeS.
Results: 7 years postpartum, the MeS prevalence was
14% (95% CI 8% to 25%) in the intervention group;
15% (CI 8% to 25%) in the usual care group; 50%
(CI 35% to 65%) in the early GDM group and 7% (CI
2% to 18%) in the healthy control group. OR for MeS
in women with GDM risk factors did not differ from the
healthy control group. Body mass index (BMI)-adjusted
OR for MeS was 9.18 (CI 1.82 to 46.20) in the early
GDM group compared with the healthy control group.
Increased prepregnancy BMI was associated with MeS
(OR, 1.17, CI 1.08 to 1.28, adjusted for group).
Conclusions: Increased prepregnancy BMI and early
GDM diagnosis were the strongest risk factors for
developing MeS 7 years postpartum. Overweight and
obese women and especially those with early GDM
should be monitored and counselled for
cardiometabolic risk factors after delivery.
INTRODUCTION
Metabolic syndrome (MeS) is a clustering of
atherosclerotic risk factors, including abdom-
inal obesity, elevated plasma triglycerides,
decreased high density lipoprotein (HDL)
cholesterol, elevated blood pressure and
elevated fasting glucose.1 2 Insulin resistance
and low-grade inﬂammation are central
drivers in the pathogenesis of MeS.3 4 In add-
ition to genetic features, obesogenic lifestyle
deﬁned by unhealthy diet and physical
inactivity increase the risk for MeS.5–9 The
prevalence of MeS is increasing worldwide,
along with the obesity epidemic and popula-
tion ageing.10 11 Estimates of MeS prevalence
vary between 15% and 34% in adult popula-
tions,12–15 and around 8–19% in reproduct-
ive-aged women in industrial countries.16–18
It is relevant to identify patients with MeS, as
they are at twice the risk for developing car-
diovascular disease over the next 5–10 years,
and at ﬁvefold lifetime risk of developing
type 2 diabetes compared with individuals
without the syndrome.1
Gestational diabetes mellitus (GDM) is a
disorder in glucose and insulin metabolism
ﬁrst diagnosed during pregnancy.19 The
most important risk factors for GDM are pre-
pregnancy overweight, high maternal age
and a family history of type 2 diabetes.20
Women with a history of GDM are at
Strengths and limitations of this study
▪ Our study was a long-term follow-up of a large
gestational diabetes mellitus (GDM) prevention
trial.
▪ The study was one of the first follow-up studies
on the prevalence of metabolic syndrome (MeS)
after delivery among women with risk factors for
GDM.
▪ The results include data of the MeS prevalence
among different risk groups.
▪ Thirty-seven per cent of the invited women
entered the measurements for MeS, and the four
subgroups were relatively small.
▪ The results may have been moderately affected
by a healthy selection bias.
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increased risk for developing cardiometabolic disorders,
such as type 2 diabetes and MeS after delivery.21 22 MeS
and GDM share mutual risk factors, suggesting that
women with risk factors for GDM may be at increased
risk for future MeS, even in the absence of GDM.23 24
Overweight and excessive gestational weight gain have
been linked to development of GDM and later cardio-
metabolic disorders.23 25–27 Long-term follow-up studies
on development of MeS among women at increased
GDM risk are lacking.
Our cluster randomised controlled trial (RCT) in
Finnish pregnant women at increased GDM risk showed
that lifestyle counselling was effective in controlling the
proportion of large-for-gestational-age new-borns and
improving the women’s diet, and preventing excessive
gestational weight gain and decrease in physical activ-
ity.28–31 One year after delivery, the prevalence of MeS
among women with GDM risk factors was 16–18%
depending on the criteria; with no differences between
the intervention and usual care group.24
Our aim is to study MeS and its components 7 years
postpartum among Finnish women who in early preg-
nancy were at increased risk of developing GDM (inter-
vention or usual care), among women with early
pregnancy GDM diagnosis and among women without
GDM risk factors during pregnancy (healthy control).
We also studied risk factors associated with the develop-
ment of MeS 7 years postpartum.
METHODS
Participants and study design
The study is a 7-year follow-up of a cluster RCT on GDM
prevention (ISRCTN33885819). Detailed descriptions
of the design and methods of the original study have
been published previously.32 The study was conducted in
14 primary healthcare maternity clinics in Western
Finland in 2007–2009, a 1-year postpartum follow-up in
2009–2011 and the 7-year follow-up in 2014–2016.
The primary aim of the trial was to prevent GDM and
excessive gestational weight gain among pregnant
women with an increased risk for GDM. Maternity
clinics were randomised into seven intervention and
seven control clinics. Pregnant women were recruited by
nurses at their ﬁrst visit (8–12 weeks’ gestation) in
maternity clinics. Women were eligible if they had at
least one of the following GDM risk factors: age≥40
years, prepregnancy body mass index (BMI) ≥25 kg/m²,
GDM or any sign of glucose intolerance in any previous
pregnancy, a macrosomic baby (≥4500 g) in any previ-
ous pregnancy or diabetes in ﬁrst-degree or second-
degree relatives. The main exclusion criteria were
age<18 years, a GDM diagnosis at 8–12 weeks’ gestation,
twin pregnancy, physical restrictions that precluded
exercise or a clinical history of chronic disease. A diag-
nosis of GDM was based on a 2-hour 75 g oral glucose
tolerance test (OGTT) according to at least one of
the following criteria: fasting plasma glucose of
≥5.3 mmol/L, >10.0 mmol/L at 1 hour or >8.6 mmol/
L at 2 hours.33
The original intervention included individual counsel-
ling on weight gain, diet and physical activity by public
health nurses during ﬁve routine visits to maternity
clinics. The women in the control clinics received usual
maternal care, which also included some lifestyle advice.
Of 888 pregnant women who participated in the base-
line assessments at 8–12 weeks’ gestation, 442 (50%)
were eligible for the original study (intervention and
usual care group) (ﬁgure 1). Further, 374 were
excluded, of whom 174 due to a GDM diagnosis at 8–12
weeks’ gestation (early GDM group). The healthy
control group consisted of 176 women who did not
meet the inclusion criteria.
Seven hundred and eighty-eight women were invited to
participate in the follow-up study 7 years (mean 7.2, range
5.6–8.3) after delivery, and 289 women participated.
The study was conducted in accordance with the
Declaration of Helsinki (2000), and it was approved by
Pirkanmaa University Hospital District Ethics (Ref.
number R14039). The participants completed a written
informed consent before participation.
Laboratory measurements
Information on maternal measurements by the nurses
was obtained from the standard maternity cards. Height
was measured at the ﬁrst maternity care visit (8–
12 weeks’ gestation), and weight was measured at each
maternity care visit, and at 1 and 7 years postpartum.
Waist circumference was measured at 1 and 7 years post-
partum, and the average of three measurements was
used in the analysis. Blood pressure was measured in
duplicate at each maternity care visit and at 1 and
7 years postpartum.
Blood samples for glucose, cholesterol, HDL choles-
terol and triglyceride analysis after a 12-hour fast, and a
2-hour OGTT were collected at baseline and at 1 and
7 years postpartum. All blood analyses were performed
at the UKK Institute. During the OGTT, the participants
drank 75 g glucose in 330 mL water (Glucodyn,
Ultimed, Finland), and the samples were taken after 60
and 120 min. Plasma glucose concentrations were mea-
sured fresh within 24 hours after the OGTT. Plasma
samples for lipid analysis were stored frozen at −80°C
until analysed. Citric acid/ﬂuoride and EDTA tubes
were used for glucose and lipid analysis of venous blood.
Glucose, total cholesterol, HDL cholesterol and triglycer-
ide concentrations were determined in enzymatic assays
using a Roche Cobas Mira Plus analyser. All testing was
performed in duplicate.
MeS was diagnosed according to International
Diabetes Federation (IDF) criteria.1 The diagnosis was
set if any three of the ﬁve criteria were present:
increased waist circumference (>80 cm); elevated trigly-
cerides (≥1.7 mmol/L), or speciﬁc medication; reduced
HDL cholesterol (<1.3 mmol/L), or speciﬁc medication,
elevated fasting glucose (≥5.6 mmol/L), or speciﬁc
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medication, and elevated blood pressure (≥130 or
85 mm Hg), or speciﬁc medication.
Statistical analyses
The background characteristics and descriptive informa-
tion on components and the prevalence of MeS are
reported as means and SDs or frequencies and propor-
tions. The Wilson score method without continuity
correction was used to calculate 95% CIs for prevalence.
A χ2 test was used to investigate whether distributions of
categorical variables differed from one another.
Continuous variables were normally distributed. We used
one-way analysis of variance to compare means across
groups. Differences in continuous variables between the
healthy control or the early GDM group compared with
the other three groups merged together were tested by
independent samples t-test. Binary logistic regression
models were used to obtain ORs and their 95% CIs to
study associations between MeS and its explanatory vari-
ables. Explanatory variables were group (the interven-
tion, the usual care, the early GDM and the healthy
control as a reference group), age (continuous), BMI
(continuous) and the ﬁve GDM risk factors which were
used in entrance criteria to the original study: BMI
≥25 kg/m², age≥40 years, GDM or any sign of glucose
intolerance in any previous pregnancy, a macrosomic
baby (≥4500 g) in any previous pregnancy, and diabetes
in ﬁrst-degree or second-degree relatives. Based on the
rule of 10 events per variable, multivariable logistic
regression models were adjusted only for BMI and GDM
or any sign of glucose intolerance in any previous preg-
nancy. The results were considered to be statistically sig-
niﬁcant if p<0.05. All analyses were performed with SPSS
software (V.20.0).
RESULTS
Background characteristics
Table 1 shows the characteristics of the 289 women who
participated in the follow-up study 7 years postpartum.
The mean age of the participants was 37.8 years (range
25–52 years) and the mean number of deliveries was 2.5
(range 1–9). Twenty-nine (10%) women smoked fre-
quently or occasionally. The most common inclusion cri-
teria for the study were prepregnancy overweight or
obesity, and diabetes in ﬁrst-degree or second-degree
relatives. Women with early GDM fulﬁl the inclusion cri-
teria of being overweight (p<0.001) and having a history
of GDM (p=0.002) more often than others. Healthy con-
trols did not meet inclusion criteria (GDM risk factors)
at baseline. The prevalence of overweight and obesity
7 years postpartum (53%, 69%, 80%) had stayed around
the same level, or slightly increased, compared with
early pregnancy (48%, 68%, 78%) among women in the
intervention, usual care and early GDM group, respect-
ively. Four women (2 in the early GDM and 2 in the
healthy control group) had medication for type 2 dia-
betes. Sixteen (5%) women had medication for dyslipi-
daemias and eight (3%) for hypertension, with no
Figure 1 Flow diagram of the study. The two intervention groups (intervention and usual care), early gestational diabetes
mellitus and healthy control groups were invited for follow-up measurements 7 years after intervention.
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difference between groups. Eighty-one (28%) women
reported hormonal contraception.
Women with early GDM had higher mean weight
(p<0.001) and BMI (p<0.001) compared with women in
the other three groups. Signiﬁcant association between
group and overweight (p<0.001) and obesity (p<0.001)
was found, so that women with early GDM were more
often overweight and obese than women in the other
groups. Healthy controls, on the other hand, had lower
mean weight (p<0.001) and lower BMI (p<0.001). They
were less often overweight or obese compared with
women in the other three groups, both of the associa-
tions being signiﬁcant (p<0.001). There were no other
between-group differences in the background character-
istics. Compared with baseline (at 8–12 weeks’ preg-
nancy), the women had gained weight on average 3.1 kg
(SD 7.0, range −33.2 to 25.1 kg). The groups did not
differ statistically signiﬁcantly from each other. The
healthy control group seemed to have had gained less
weight than the other three groups (1.8 vs 3.5, p=0.13).
Twelve (9%) women of the intervention group and
seven (5%) women of the usual care group and none of
the healthy control group had been diagnosed for GDM
at 26–28 weeks’ pregnancy.
MeS and its components 7 years postpartum
The prevalence of MeS among all women was 19%
(95% CI 15% to 25%) (table 2). Among women with
GDM risk factors, the prevalence was 14% (95% CI 9%
to 21%), with no difference between the intervention
(14%, 95% CI 8% to 25%) and the usual care group
(15%, 95% CI 8% to 25%). The prevalence was highest
among the early GDM group (50%, 95% CI 35% to
65%) and lowest among the healthy control group (7%,
95% CI 2% to 18%). Two (11%) of the 19 women with
the GDM diagnosis at 26–28 weeks’ gestation had MeS
at 7 years postpartum.
Seventy-two per cent of the women exceeded the waist
circumference limit of 80 cm (increased waist circumfer-
ence) and almost half exceeded the limit of 88 cm
(abdominal obesity). HDL was reduced (≤1.3 mmol/L)
among half of the women. All women with the MeS
diagnosis exceeded the waist circumference of 80 cm.
Women in the early GDM group had a larger mean
waist circumference (p<0.001), higher fasting glucose
(p<0.001), higher systolic blood pressure (p=0.047) and
higher TG (p<0.0001). They more often exceeded the
limits for increased waist circumference and abdominal
obesity (p<0.001 and p=0.002), impaired fasting glucose
(p<0.001) and increased TG (p<0.001) compared with
the three other groups. Healthy controls had a smaller
mean waist circumference (p<0.001), lower systolic
(p=0.01) and diastolic (p=0.03) blood pressure and
higher HDL (p=0.02), and they less often exceed the
limits for increased waist circumference (p<0.001) and
decreased HDL (p=0.03) compared with the other
Table 1 Background characteristics of women at 7 years postpartum
Intervention
(n=83)
Usual care
(n=87)
Early GDM
(n=51)
Healthy control
(n=68)
All
(n=289)
Age (years) 37.7±4.5 38.0±4.9 38.6±4.3 37.0±5.2 37.8±4.8
Weight (kg) 75.6±17.3 76.9±13.1 84.5±16.3 62.9±7.6 74.6±15.7
BMI (kg/m2) 27.2±5.5 28.1±5.1 30.1±5.6 22.7±2.5 26.9±5.4
BMI 25–29.9 kg/m2 17 (20) 39 (45) 41 (35) 12 (18) 86 (29)
BMI ≥30 kg/m2 27 (33) 21 (24) 23 (45) 0 (0) 71 (25)
Smoking
No 73 (91) 77 (91) 45 (94) 57 (84) 252 (90)
Occasionally or daily 7 (9) 8 (9) 3 (6) 11 (16) 29 (10)
Education
Basic or secondary education 25 (31) 25 (28) 19 (37) 20 (31) 89 (31)
Polytechnic education 28 (34) 40 (46) 20 (39) 29 (45) 117 (41)
University degree 29 (35) 23 (26) 13 (25) 16 (25) 81 (28)
Parity 2.4±1.0 2.6±1.2 2.6±1.6 2.5±1.0 2.5±1.2
1 8 (10) 12 (14) 6 (13) 6 (9) 32 (12)
2–3 66 (84) 60 (71) 35 (74) 50 (75) 211 (76)
≥4 5 (6) 12 (14) 6 (13) 11 (16) 34 (12)
GDM risk criteria (at 8–12 weeks’
pregnancy)
BMI ≥25 kg/m2 40 (48) 59 (68) 39 (78) NA 138 (48)
Macrosomic child in any previous
pregnancy
3 (4) 3 (3) 5 (10) NA 11 (4)
GDM in any previous pregnancy 13 (16) 7 (8) 13 (39) NA 33 (12)
Diabetes in first-degree or
second-degree relatives
53 (64) 43 (49) 25 (50) NA 121 (42)
Age ≥40 years 3 (4) 5 (6) 0 (0) NA 8 (3)
Means and SDs or frequencies (and proportions) of participants (n=289). BMI, body mass index; GDM, gestational diabetes mellitus.
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groups. There were no differences in the components
MeS between the intervention and usual care groups.
Fifty-ﬁve (27%) women did not meet the criteria for
any MeS component: 14 (23%) women in the interven-
tion group, 14 (22%) in the usual care group, 7 (18%)
in the early GDM group and 20 (46%) in the healthy
control group. Most women (n=115, 56%) met one or
two MeS components.
Risk factors of MeS
Univariable binary logistic regression models
In univariable logistic regression models, the OR for
developing MeS 7 years postpartum among women with
increased GDM risk during pregnancy (intervention and
usual care) did not differ statistically signiﬁcantly from
the healthy control group (table 3). OR for MeS among
women with early GDM was 21.0 (95% CI 4.47 to 98.7)
compared with the healthy controls, and 6.0 (95% CI
2.7 to 13.2) compared with the intervention and the
usual care groups (not presented). Prepregnancy BMI
(OR 1.20, 95% CI 1.11 to 1.29, p<0.001), prepregnancy
overweight or obesity (OR 8.06, 95% CI 3.21 to 20.2,
p<0.001) and GDM or any sign of glucose intolerance in
any previous pregnancy (OR 3.21, 95% CI 1.34 to 7.69,
p<0.01) were associated with increased occurrence of
MeS. The other GDM risk factors (macrosomic baby in
any previous pregnancy, diabetes in relatives or age)
were not associated with the MeS occurrence 7 years
postpartum.
Multivariable binary logistic regression models
In a multivariable regression model 1, adjusted for pre-
pregnancy BMI, the OR for developing MeS 7 years
postpartum among women with increased GDM risk
during pregnancy (intervention and usual care) did not
differ signiﬁcantly from the healthy control group
(table 3). Women with early pregnancy GDM had
increased odds for MeS compared with the healthy
control group (OR 9.18, 95% CI 1.82 to 46.20, p=0.007).
Also increased prepregnancy BMI was associated with
increased odds for MeS (OR 1.20, 95% CI 1.11 to 1.29,
p<0.001). In a multivariable regression model 2,
adjusted for BMI and GDM or any sign of glucose
intolerance in any previous pregnancy, early GDM when
compared with the healthy control group (OR 97.75,
95% CI 1.50 to 40.0, p=0.014), and increased prepreg-
nancy BMI (OR 1.19, 95% CI 1.09 to 1.31, p<0.001)
were associated with the MeS occurrence. GDM or any
sign of glucose intolerance in any previous pregnancy
was not associated with the MeS occurrence 7 years
postpartum.
Dropout analyses
Data for 7-year follow-up for MeS were available for 37%
of the women who were invited to participate after 7
years (n=788). Of the women invited to follow-up study,
17% were not willing to participate, 26% were out of
reach and 20% only completed a follow-up question-
naire. Dropout analyses showed that the women partici-
pating the 7-year follow-up study were older at the
baseline (30.2 vs 29.2, p<0.01), were less often frequent
or occasional smokers before pregnancy (17% vs 30%,
p<0.001) and were higher educated (university degree
28% vs 19%, p<0.009) compared with the non-
participants. There were no differences between the
groups in other background characteristic (BMI, parity
Table 2 Components of metabolic syndrome (MeS) and the prevalence of MeS according to International Diabetes
Federation criteria
Intervention
(n=64–74)
Usual care
(n=66–78)
Early GDM
(n=40–45)
Healthy
control
(n=44–51)
All
(n=217–248)
Missing
values (N)*
Waist circumference (cm)* 89.9±13.0 90.9±12.8 97.9±14.6 79.5±6.5 89.5±13.5 0, 3, 0, 0
Waist ≥80 cm 52 (70) 59 (79) 42 (93) 24 (47) 177 (72)
Waist ≥88 cm 41 (55) 42 (56) 32 (71) 6 (12) 121 (49)
Fasting glucose (mmol/L) 5.2±0.5 5.2±0.4 5.6±0.5 5.2±0.4 5.3±0.5 5, 12, 3, 6
Fasting glucose ≥5.6 mmol/L or
medication
10 (15) 7 (11) 21 (49) 4 (9) 42 (19)
Systolic pressure (mm Hg) 119±13 118±12 122±11 114±14 118±12 2, 3, 1, 4
Diastolic pressure (mm Hg) 77±10 78±10 79±7 75±10 77±10 2, 3, 1, 4
Blood pressure ≥130 or
≥85 mm Hg or medication
10 (14) 13 (17) 8 (18) 6 (13) 37 (16)
HDL cholesterol (mmol/L) 1.30±0.27 1.28±0.38 1.28±0.36 1.41±0.30 1.32±0.34 10, 0, 2, 1
HDL cholesterol ≤1.3 mmol/L
or medication
33 (52) 41 (53) 25 (58) 18 (36) 117 (50)
Triglycerides (mmol/L) 0.91±0.34 1.05±0.67 1.36±0.88 0.95±0.38 1.05±0.61 10, 0, 2, 1
Triglycerides ≥1.7 mmol/L 1 (2) 9 (12) 12 (28) 5 (10) 27 (12)
Metabolic syndrome 9 (14) 10 (15) 20 (50) 3 (7) 42 (19) 10, 7, 5, 7
Means and SDs or frequencies (and proportions) of participants. GDM, gestational diabetes mellitus.
*Number of missing values in the intervention, usual care, early GDM, healthy control groups, respectively.
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or GDM risk criteria), laboratory measurements or
group distribution.
DISCUSSION
Seven years postpartum, MeS was diagnosed among 14%
(95% CI 9% to 21%) of the women with risk factors for
GDM during pregnancy. The MeS prevalence was
highest among women with a diagnosis of early GDM
(50%, 95% CI 35% to 65%), and lowest among the
healthy control group (7%, 95% CI 2% to 18%).
Diagnosis of early GDM and increased prepregnancy
BMI were the strongest risk factors for developing MeS.
Prepregnancy and present overweight or obesity were
common among women with GDM risk factors, and
especially among those with early GDM.
In a prospective Finnish population study among
women aged 36 and 39, the MeS prevalence was 18%
and 23% according to the IDF deﬁnition.18 Compared
with these levels, the MeS prevalence in our study was
somewhat lower among women with an increased risk
for GDM. Therefore, increased GDM risk seemed not to
be associated with a higher MeS prevalence 7 years post-
partum. Compared with the women aged 35–45 and 25–
60 years in a Finnish population study in 2012, however,
the women with increased GDM risk were more often
obese (28% vs 16%),34 and abdominally obese (waist cir-
cumference >88 cm) (56% vs 30%).35 These differences
are relevant, as especially abdominal obesity is the most
important independent factor in the development of
MeS.10 The ﬁnding may indicate future risk in our parti-
cipants. Overweight was also the most common inclusion
criteria (GDM risk criteria) in our study, which appar-
ently had an inﬂuence on the high prevalence of over-
weight and obesity postpartum.
However, the intervention (14%, 95% CI 8% to 25%)
and usual care (15%, 95% CI 8% to 25%) group did
not differ from each other in the prevalence of MeS or
its components after 7 years, even though counselling
had positive effects on women’s weight gain and lifestyle
during pregnancy.28–31 However, 7 years are a long time,
and several factors have affected women’s lifestyle.
Mothers with small children may have had lack of time
and may have got tired to follow the recommended life-
style habits which were discussed during the interven-
tion. Further, participation in a GDM prevention study
may have improved health consciousness and lifestyle
habits in the intervention and the usual care group.
Additionally, also usual care includes some lifestyle coun-
selling in Finland. Dropout rate was rather high, but
since it was non-differential for group, the possibility for
bias in the differences between groups remains low.
Our subgroups differed in the prevalence of MeS.
Women in the early GDM and women in the healthy
control groups represented the extremes (50% vs 7%).
Earlier studies have found that history of GDM is
strongly associated with a higher risk of future MeS and
other cardiometabolic disorders.36 37 In a Finnish
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cohort among 240 women, the risk of developing MeS
2–6 years after pregnancy complicated by GDM was
2.4-fold higher compared with normal pregnancy.21
In our earlier report of the same original trial, the
MeS prevalence among women with early GDM was
already elevated (31%) at 1-year postpartum compared
with the intervention group (11%).24 Seven years
postpartum, the MeS prevalence among women with
early GDM had increased to 50%. Further, women
with early GDM had increased odds for MeS compared
with other three groups (intervention, usual care and
healthy controls). The association remained after
adjustment for BMI. Also history of GDM was associated
with the MeS occurrence. These ﬁndings attest the
later cardiometabolic risk associated with GDM.
Nevertheless, GDM diagnosis at 26–28 weeks’ gestation
among the 19 women in the intervention and usual
care group seemed not to be associated with higher
MeS prevalence in our data. Therefore, our study sug-
gests that GDM was associated with an increased MeS
prevalence 7 years postpartum if it was diagnosed in
early pregnancy (8–12 weeks). Women with early GDM
are a special high risk group for later cardiometabolic
disorders. A large meta-analysis found that women with
early pregnancy GDM were at a twofold risk for future
type 2 diabetes compared with women with later
GDM.26
Several cardiometabolic risk factors were clustered in
the women in the early GDM group. In early pregnancy,
they had been more often overweight or obese, and
7 years postpartum, they still were more often overweight
or obese, and had components of MeS more frequently
than the other women. Further, compared with Finnish
female population, the women with early GDM in our
study were three times more often obese (45% vs
16%),34 and over two times more often abdominally
obese (waist circumference >88cm) (71% vs 30%).35
Present obesity partly explains the increased MeS preva-
lence. Clustering of lifestyle-related risk factors is
common.38–40 Pregnancy-related weight retention tends
to be highest among those women who have been over-
weight or obese before pregnancy.41 42 Further, many
women retain weight after pregnancy, and the mean
weight gain associated with parity is around 0.5–3.2 kg,
with a high personal variation.39 43 44 In a Finnish popu-
lation study, parity-related weight retention was asso-
ciated with visceral obesity.45
High prevalence of obesity promoting insulin resist-
ance was probably the common denominator for the
increased prevalence of early pregnancy GDM and MeS
after 7 years.46 47 This ﬁnding clearly underlines that it
is particularly important to invest in lifestyle counselling
among overweight and obese pregnant women entering
maternity care. Prevention of excessive weight gain
during pregnancy and promoting postpartum weight
reduction by individually tailored lifestyle modiﬁcations
have been effective against weight retention, and in pre-
venting further cardiometabolic disorders, such as MeS
in parous women.48–52 A weight reduction of 5–10% is
associated with signiﬁcant decreases in cardiometabolic
risk factors.53 54 The possibilities for reaching pregnant
women in many countries are good due to maternity
care systems, but there is often lack of long-term
follow-up as the healthcare providers change.55 Actions
to increase cooperation between different providers are
needed.
Healthy controls were healthier than the other three
groups with GDM risk factors, as assessed by com-
ponents and the prevalence of MeS at 7 years post-
partum. Also compared with the Finnish population,
they represented an unexceptionally healthy group, in
what comes to the prevalence of obesity (0% vs 16%),
abdominal obesity (12% vs 30%) as well as MeS (7% vs
17–23%).34 35 The results suggest that keeping normal
weight and prevention of excessive pregnancy-related
weight retention are important in not only preventing
GDM, but also in preventing later MeS.
Strengths and limitations
Our study has several strengths. It was a long-term
follow-up, from early pregnancy until 7 years post-
partum. It was also one of the ﬁrst follow-up studies of
gestational trials, in which the prevalence of MeS has
been determined among women with risk factors for
GDM. To the best of our knowledge, the only previous
follow-up report was ours on the MeS prevalence among
women with GDM risk factors at 1-year postpartum.24 In
general, there is a limited amount of studies of the MeS
prevalence among reproductive-aged female popula-
tions, even though obesity is rapidly increasing world-
wide, especially among young adults.11 56 Our study
results include data of the MeS prevalence among differ-
ent risk groups—women with an increased GDM risk,
women diagnosed with early GDM and healthy pregnant
women. Also associations between risk factors assessed in
early pregnancy and MeS 7 years postpartum have not
been identiﬁed earlier. Our original trial32 was one of
the largest RCTs about preventing the development of
GDM in women with GDM risk factors.
After 7 years, the recruitment of the women of the ori-
ginal study was difﬁcult, and eventually, 37% of the
invited women entered the measurements for analyses
of MeS. Thirty-seven per cent were either not willing to
participate or only completed the follow-up question-
naire. Dropout analyses showed that the results may have
been affected by a healthy selection bias, as the women
who participated in the follow-up study were less often
smokers and were higher educated. On the other hand,
the bias affected all four subgroups entering the
follow-up study, as they did not differ from each other
regarding to the participation rate. The subgroups were
relatively small, which weakened the power to compare
the subgroups. The study was implemented among
Finnish women, and thus, the results can only be gener-
alised to Caucasian populations.
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CONCLUSIONS
Seven years postpartum, MeS was diagnosed among 14%
of the women with risk factors for GDM during preg-
nancy, which is less than average. The MeS prevalence
was the highest among women with a diagnosis of early
GDM (50%), and the lowest among the healthy control
group (7%). Early GDM diagnosis and increased pre-
pregnancy BMI were the strongest risk factors for devel-
oping MeS. Prepregnancy and present overweight or
obesity were common among women with GDM risk
factors, and especially among those with early GDM.
Overweight and obese women and especially those with
early GDM should be monitored and counselled for car-
diometabolic risk factors after delivery. Prevention of
pregnancy-related weight retention, including excessive
gestational and postpartum weight gain, is important for
the prevention of MeS. Overweight and obesity among
reproductive-aged women is increasing, which represents
even a greater challenge in monitoring and managing
risk factors for chronic diseases. Larger population
studies on the MeS prevalence and evaluation of preven-
tion strategies are needed among reproductive-aged
women, especially among those with GDM risk factors.
Acknowledgements The authors thank hospital chemist, Anne Rauhio, from
Fimlab Laboratories who was responsible for the laboratory testing. Päivi
Viitanen, Taru Helenius, Ulla Hakala, Ulla Honkanen and Sirke Rasinperä
recruited the study participants, participated in the data collection and
managed the study data.
Contributors RL, JP, PK, PT and PH initiated the study design; JR and JP
performed statistical analyses; JP wrote the paper. All authors contributed to
refinement of the study protocol and approved the final manuscript. JP and
RL have the primary responsibility for the final content.
Funding This work was supported by Academy Finland (grant number
277079), Competitive Research Funding of the Tampere University Hospital
(9R030, 9S034, 9N041, 9M053) and the Juho Vainio Foundation.
Competing interests None declared.
Ethics approval Pirkanmaa University Hospital District Ethics.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All data presented in this study are available for
further collaboration after request to RL (riitta.luoto@uta.fi).
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National
Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity. Circulation
2009;120:1640–5.
2. Silva V, Stanton KR, Grande AJ. Harmonizing the diagnosis of
metabolic syndrome—focusing on abdominal obesity. Metab Syndr
Relat Disord 2013;11:102–8.
3. Esser N, Paquot N, Scheen AJ. Inflammatory markers and
cardiometabolic diseases. Acta Clin Belg 2015;70:193–9.
4. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as
the underlying cause for the metabolic syndrome. Mt Sinai J Med
2010;77:511–23.
5. Edwardson CL, Gorely T, Davies MJ, et al. Association of sedentary
behaviour with metabolic syndrome: a meta-analysis. PLoS ONE
2012;7:e34916.
6. Moreira GC, Cipullo JP, Ciorlia LA, et al. Prevalence of metabolic
syndrome: association with risk factors and cardiovascular
complications in an urban population. PLoS ONE 2014;9:e105056.
7. Bassi N, Karagodin I, Wang S, et al. Lifestyle modification for
metabolic syndrome: a systematic review. Am J Med 2014;127:1242.
e1–10.
8. Takahara M, Shimomura I. Metabolic syndrome and lifestyle
modification. Rev Endocr Metab Disord 2014;15:317–27.
9. Brown AE, Walker M. Genetics of insulin resistance and the
metabolic syndrome. Curr Cardiol Rep 2016;18:75.
10. Han TS, Lean ME. A clinical perspective of obesity, metabolic
syndrome and cardiovascular disease. JRSM Cardiovasc Dis
2016;5:2048004016633371.
11. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the
growing epidemic and its associated pathologies. Obes Rev
2015;16:1–12.
12. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The
prevalence of metabolic syndrome and metabolically healthy obesity
in Europe: a collaborative analysis of ten large cohort studies.
BMC Endocr Disord 2014;14:9.
13. Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic
syndrome in the united states, 2003–2012. JAMA 2015;313:
1973–4.
14. Harris MF. The metabolic syndrome. Aust Fam Physician
2013;42:524–7.
15. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome:
prevalence in worldwide populations. Endocrinol Metab Clin
North Am 2004;33:351–75. table of contents.
16. Broderstad AR, Melhus M. Prevalence of metabolic syndrome
and diabetes mellitus in Sami and Norwegian populations. The
SAMINOR—a cross-sectional study. BMJ Open 2016;6:e009474.
17. Alkerwi A, Donneau AF, Sauvageot N, et al. Prevalence of the
metabolic syndrome in Luxembourg according to the Joint Interim
Statement definition estimated from the ORISCAV-LUX study.
BMC Public Health 2011;11:4.
18. Raiko JR, Viikari JS, Ilmanen A, et al. Follow-ups of the
Cardiovascular Risk in Young Finns Study in 2001 and 2007: levels
and 6-year changes in risk factors. J Intern Med 2010;267:370–84.
19. American Diabetes Association. (2) Classification and diagnosis of
diabetes. Diabetes Care 2015;(Suppl 38):S8–16.
20. Kampmann U, Madsen LR, Skajaa GO, et al. Gestational diabetes:
a clinical update. World J Diabetes 2015;6:1065–72.
21. Vilmi-Kerälä T, Palomäki O, Vainio M, et al. The risk of metabolic
syndrome after gestational diabetes mellitus—a hospital-based
cohort study. Diabetol Metab Syndr 2015;7:1–10.
22. Xu Y, Shen S, Sun L, et al. Metabolic syndrome risk after gestational
diabetes: a systematic review and meta-analysis. PLoS ONE
2014;9:e87863.
23. Durnwald C. Gestational diabetes: linking epidemiology, excessive
gestational weight gain, adverse pregnancy outcomes, and future
metabolic syndrome. Semin Perinatol 2015;39:254–8.
24. Puhkala J, Kinnunen TI, Vasankari T, et al. Prevalence of metabolic
syndrome one year after delivery in Finnish women at increased risk
for gestational diabetes mellitus during pregnancy. J Pregnancy
2013;2013:139049.
25. Gilmore LA, Klempel-Donchenko M, Redman LM. Pregnancy as a
window to future health: excessive gestational weight gain and
obesity. Semin Perinatol 2015;39:296–303.
26. Rayanagoudar G, Hashi AA, Zamora J, et al. Quantification of the
type 2 diabetes risk in women with gestational diabetes: a
systematic review and meta-analysis of 95,750 women. Diabetologia
2016;59:1403–11.
27. Puhkala J, Luoto R, Ahotupa M, et al. Postpartum weight retention
is associated with elevated ratio of oxidized LDL lipids to
HDL-cholesterol. Lipids 2013;48:1227–35.
28. Kinnunen TI, Puhkala J, Raitanen J, et al. Effects of dietary
counselling on food habits and dietary intake of Finnish pregnant
women at increased risk for gestational diabetes—a secondary
analysis of a cluster-randomized controlled trial. Matern Child Nutr
2014;10:184–97.
29. Aittasalo M, Raitanen J, Kinnunen TI, et al. Is intensive counseling
in maternity care feasible and effective in promoting physical activity
among women at risk for gestational diabetes? Secondary analysis
of a cluster randomized NELLI study in Finland. Int J Behav Nutr
Phys Act 2012;9:104.
8 Puhkala J, et al. BMJ Open 2017;7:e014565. doi:10.1136/bmjopen-2016-014565
Open Access
group.bmj.com on May 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
30. Kinnunen TI, Raitanen J, Aittasalo M, et al. Preventing
excessive gestational weight gain–a secondary analysis
of a cluster-randomised controlled trial. Eur J Clin Nutr
2012;66:1344–50.
31. Luoto R, Kinnunen TI, Aittasalo M, et al. Primary prevention of
gestational diabetes mellitus and large-for-gestational-age newborns
by lifestyle counseling: a cluster-randomized controlled trial.
PLoS Med 2011;8:e1001036.
32. Luoto RM, Kinnunen TI, Aittasalo M, et al. Prevention of gestational
diabetes: design of a cluster-randomized controlled trial and
one-year follow-up. BMC Pregnancy Childbirth 2010;10:39.
33. American Diabetes Association. Diagnosis and classification of
diabetes mellitus. Diabetes Care 2006;(29 Suppl 1):S43–8.
34. Borodulin K, Levälahti E, Saarikoski L, et al. Kansallinen FINRISKI
2012—terveystutkimus—Osa 2: Tutkimuksen taulukkoliite.
Terveyden ja hyvinvoinnin laitos, Helsinki. (In Finnish). 2013; 22.
http://urn.fi/URN:ISBN:978-952-302-054-2 (accessed 30 Jun 2016).
35. Männistö S, Laatikainen T, Vartiainen E. Suomalaisten lihavuus
ennen ja nyt. Tutkimuksesta tiiviisti 4, marraskuu 2012.Terveyden ja
hyvinvoinnin laitos, Helsinki. (In Finnish). 2012. http://urn.fi/URN:
ISBN:978-952-245-792-9 (accessed 30 Jun 2016).
36. Sullivan SD, Umans JG, Ratner R. Gestational diabetes: implications
for cardiovascular health. Curr Diab Rep 2012;12:43–52.
37. Akinci B, Celtik A, Yener S, et al. Prediction of developing metabolic
syndrome after gestational diabetes mellitus. Fertil Steril
2010;93:1248–54.
38. Althuizen E, van Poppel MN, de Vries JH, et al. Postpartum
behaviour as predictor of weight change from before pregnancy to
one year postpartum. BMC Public Health 2011;11:165.
39. Wolfe WS, Sobal J, Olson CM, et al. Parity-associated body weight:
modification by sociodemographic and behavioral factors. Obes Res
1997;5:131–41.
40. Ohlin A, Rössner S. Factors related to body weight changes during
and after pregnancy: the Stockholm Pregnancy and Weight
Development Study. Obes Res 1996;4:271–6.
41. Siega-Riz AM, Viswanathan M, Moos MK, et al. A systematic review
of outcomes of maternal weight gain according to the Institute
of Medicine recommendations: birthweight, fetal growth, and
postpartum weight retention. Am J Obstet Gynecol 2009;201:339.
e1–14.
42. Margerison Zilko CE, Rehkopf D, Abrams B. Association of
maternal gestational weight gain with short- and long-term
maternal and child health outcomes. Am J Obstet Gynecol
2010;202:574.e1–8.
43. Brown WJ, Hockey R, Dobson AJ. Effects of having a baby on
weight gain. Am J Prev Med 2010;38:163–70.
44. Gore SA, Brown DM, West DS. The role of postpartum weight
retention in obesity among women: a review of the evidence.
Ann Behav Med 2003;26:149–59.
45. Luoto R, Männistö S, Raitanen J. Ten-year change in the
association between obesity and parity: results from The National
FINRISK Population Study. Gend Med 2011;8:399–406.
46. Hakkarainen H, Huopio H, Cederberg H, et al. The risk of metabolic
syndrome in women with previous GDM in a long-term follow-up.
Gynecol Endocrinol 2016;32:920–5.
47. Mission JF, Marshall NE, Caughey AB. Pregnancy risks associated
with obesity. Obstet Gynecol Clin North Am 2015;42:335–53.
48. Hoedjes M, Berks D, Vogel I, et al. Preferences for postpartum
lifestyle counseling among women sharing an increased
cardiovascular and metabolic risk: a focus group study. Hypertens
Pregnancy 2011;30:83–92.
49. Phelan S. Windows of opportunity for lifestyle interventions to prevent
gestational diabetes mellitus. Am J Perinatol 2016;33:1291–9.
50. Guo J, Chen JL, Whittemore R, et al. Postpartum lifestyle
interventions to prevent type 2 diabetes among women with history
of gestational diabetes: a systematic review of randomized clinical
trials. J Womens Health (Larchmt) 2016;25:38–49.
51. van der Pligt P, Willcox J, Hesketh KD, et al. Systematic review of
lifestyle interventions to limit postpartum weight retention:
implications for future opportunities to prevent maternal overweight
and obesity following childbirth. Obes Rev 2013;14:792–805.
52. Phelan S, Phipps MG, Abrams B, et al. Does behavioral intervention
in pregnancy reduce postpartum weight retention? Twelve-month
outcomes of the Fit for Delivery randomized trial. Am J Clin Nutr
2014;99:302–11.
53. Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of
the effect of weight loss on all-cause mortality risk. Nutr Res Rev
2009;22:93–108.
54. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity
with specific focus on cardiovascular disease: a statement for
professionals from the American Heart Association Council on
Nutrition, Physical Activity, and Metabolism: endorsed by the
American College of Cardiology Foundation. Circulation
2004;110:2952–67.
55. Pierce M, Modder J, Mortagy I, et al. Missed opportunities for
diabetes prevention: post-pregnancy follow-up of women with
gestational diabetes mellitus in England. Br J Gen Pract 2011;61:
e611–19.
56. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult
body-mass index in 200 countries from 1975 to 2014: a pooled
analysis of 1698 population-based measurement studies with 19.2
million participants. Lancet 2016;387:1377–96.
Puhkala J, et al. BMJ Open 2017;7:e014565. doi:10.1136/bmjopen-2016-014565 9
Open Access
group.bmj.com on May 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
trial
years after a gestational diabetes prevention
 Metabolic syndrome in Finnish women 7
and Riitta Luoto
Jatta Puhkala, Jani Raitanen, Päivi Kolu, Pipsa Tuominen, Pauliina Husu
doi: 10.1136/bmjopen-2016-014565
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/3/e014565
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/3/e014565
This article cites 52 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (310)Nutrition and metabolism
 (379)Diabetes and Endocrinology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
